Provectus Biopharmaceuticals, Inc. announced the publication of preclinical research by Christine Chung, MD, and her team at Moffitt Cancer Center. The study, published in Molecular Cancer Therapeutics, evaluated intratumoral PV-10 in models of head and neck squamous cell carcinoma (HNSCC).
The research highlights novel mechanistic findings, specifically PV-10's ability to induce immunogenic cell death in HNSCC. This scientific validation adds to the understanding of PV-10's effects and supports its broad immunotherapy platform.
Dominic Rodrigues, President and Vice Chair of the Board of Directors of Provectus, stated that these results align with the company's strategy, including a planned Phase 1 trial of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt, potentially later this year. The publication provides a strong scientific foundation for further clinical development of PV-10.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.